Skip to content
Screener

Glaukos GKOS Net Income

Net Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.53B-0.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.3B-6.8%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
-$4.45M+62.8%
AbbVie logo
AbbVieABBV
$3.62B+284%
Schering-Plough logo
Schering-PloughSGP
-$13.82M-56.6%
Bausch + Lomb logo
Bausch + LombBLCO
-$10M+82.8%

Segments

By segment

See full
Development And Commercialization Of Ophthalmic Therapies-$18.38M+6.5%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemCommon stock / SharesCommon stock / AmountAdditionalpaid-in / capitalAccumulated othercomprehensive / incomeAccumulated / deficitTreasury stock / SharesTreasury stock / AmountTotal / equity
Common stock issued under stock plans, net848-16,072----16,072
Stock-based compensation--19,144----19,144
Other comprehensive loss---(660)---(660)
Net loss----(19,783)--(19,783)
Balance at March 31, 202658,387$58$1,621,272$2,643$(952,913)(28)$(132)$670,928
Common stock issued under stock plans, net49911,328----1,329
Stock-based compensation--28,865----28,865
Other comprehensive loss---(259)---(259)

Item 1. Financial Statements

FAQ

What is Glaukos's net income?
Glaukos (GKOS) reported net income of -$18.38M in Q2 2026.
How has Glaukos's net income changed year-over-year?
Glaukos's net income increased by 6.5% year-over-year, from -$19.66M to -$18.38M.
What is the long-term trend for Glaukos's net income?
Over 4 years (2021 to 2025), Glaukos's net income has grown at a 39.5% compound annual growth rate (CAGR), from -$49.59M to -$187.69M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Glaukos's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude